Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103407 | 0.74 | LMNA (0.50) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL102894 | 0.72 | AKR1B1 (0.36) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL105693 | 0.70 | AKR1B1 (0.43) | AKR1B1LMNAMEN1KMT2A | |
| SCHEMBL543048 | 0.69 | LMNA (0.48) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL104120 | 0.68 | LMNA (0.47) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL4317934 | 0.67 | LMNA (0.46) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL10200953 | 0.66 | MEN1 (0.39) | AKR1B1LMNAMEN1KMT2A | |
| SCHEMBL10321749 | 0.65 | PTGER3 (0.40) | MAPTAKR1B1LMNAMEN1KMT2A | |
| SCHEMBL101672 | 0.65 | LMNA (0.47) | AKR1B10MAPTAKR1A1AKR1B1LMNA | |
| SCHEMBL102280 | 0.65 | LMNA (0.50) | MAPTAKR1B1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | AKR1B10 495/4885MAPT 2589/4885AKR1A1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.